Gold Prices Slip as Strong Dollar and High Treasury Yields Weigh 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Trump Opens Tax-Exempt Dyed Diesel Access as Fuel Prices Surge 
Heritage, desire and diplomacy: why China still values scotch whisky 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Evernorth XRPN Nasdaq Listing Delayed to October 12 
Iceland 4x4 Rental Guide: When Do You Really Need Four-Wheel Drive? 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Indian Stocks Fall as RBI Hikes Rates to 5.50% 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
FDA Weighs Safety Standards for Psychedelic Therapies 
Intel Reaffirms Role in Elon Musk’s Terafab Chip Project 
Add as a preferred source on Google
Starbucks denies that its decision to stop selling Chicken, Maple Butter, and Egg Sandwich on June 26, a mere five days after it had been announced as a new permanent menu item, was due to FDA recall or salmonella or listeria contamination.
A Starbucks spokesperson said that the Chicken, Maple Butter, and Egg Sandwich was given a voluntary stop sell and discard order by the company because it didn't live up to the company's high standards for quality.
The quality issue that was identified by Starbucks was simply about taste or based on another issue and would not lead to food-borne illness and any reports linking the stop sale to illness are inaccurate.
The spokesperson added that Starbucks is devoted to providing high-quality products, and anytime a concern about a product or its quality is expressed, we always proceed with extreme caution.
